Founded in 2007 in Hamburg, Germany, Mulligan BioCapital invests in late-stage ventures in the life sciences sector, particularly in biotechnology. Their portfolio includes companies such as DIREVO Industrial Biotechnology, Spinal Cord Therapeutics GmbH, 4-Antibody AG, 4SC, and Cardion. With six investments made to date, the firm has had notable exits with 4SC, DIREVO Industrial Biotechnology, and 4-Antibody AG.